GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » StemRIM Inc (TSE:4599) » Definitions » Debt-to-Equity

StemRIM (TSE:4599) Debt-to-Equity : 0.00 (As of Jan. 2024)


View and export this data going back to 2019. Start your Free Trial

What is StemRIM Debt-to-Equity?

StemRIM's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was 円0 Mil. StemRIM's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was 円0 Mil. StemRIM's Total Stockholders Equity for the quarter that ended in Jan. 2024 was 円9,818 Mil. StemRIM's debt to equity for the quarter that ended in Jan. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for StemRIM's Debt-to-Equity or its related term are showing as below:

During the past 7 years, the highest Debt-to-Equity Ratio of StemRIM was 0.01. The lowest was 0.00. And the median was 0.00.

TSE:4599's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

StemRIM Debt-to-Equity Historical Data

The historical data trend for StemRIM's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StemRIM Debt-to-Equity Chart

StemRIM Annual Data
Trend Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Debt-to-Equity
Get a 7-Day Free Trial 0.01 - - - -

StemRIM Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of StemRIM's Debt-to-Equity

For the Biotechnology subindustry, StemRIM's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StemRIM's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, StemRIM's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where StemRIM's Debt-to-Equity falls into.



StemRIM Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

StemRIM's Debt to Equity Ratio for the fiscal year that ended in Jul. 2023 is calculated as

StemRIM's Debt to Equity Ratio for the quarter that ended in Jan. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


StemRIM  (TSE:4599) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


StemRIM Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of StemRIM's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


StemRIM (TSE:4599) Business Description

Traded in Other Exchanges
N/A
Address
7-15 Ayato Bio Incubator 3rd floor, Ayato Asagi 7-chome, Prefecture Ibaraki City, Osaka, JPN, 567-0085
StemRIM Inc is a biotechnology company engaged in developing regeneration-guided medicines. The business activity of the group includes research, development, manufacture, and sales of pharmaceuticals and medical devices and products such as gene therapy that activate stem cells existing in the body and induce regeneration of damaged tissue.

StemRIM (TSE:4599) Headlines

No Headlines